Poor Lung Function Tied to Asthma Exacerbations
Drug Topics
OCTOBER 7, 2022
Early interventions might preserve lung function, particularly in younger patients with frequent asthma exacerbations, say authors.
Drug Topics
OCTOBER 7, 2022
Early interventions might preserve lung function, particularly in younger patients with frequent asthma exacerbations, say authors.
PharmaVoice
OCTOBER 7, 2022
Pharma execs share their tips for being a better leader.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
OCTOBER 7, 2022
SingleCare's 4th annual celebration of the best in pharmacy, from pharmacists to pharmacy technicians and teams across the United States has been announced.
PhRMA
OCTOBER 7, 2022
PhRMA submitted comments this week in response to the Department of Health & Human Services (HHS) proposed rule on the Nondiscrimination in Health Programs and Activities. As outlined in our comments, PhRMA supports many policies in the proposed rule that aim to combat discrimination in health programs and activities, including broad application of nondiscrimination provisions, promoting health equity and preventing discriminatory benefit designs.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
OCTOBER 7, 2022
Pre-pandemic survey examines effects of heart disease, asthma, and more.
Pharmacy Times
OCTOBER 7, 2022
New research suggests that MDMA may offer promising benefits to patients with certain unmet psychological treatment needs.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
OCTOBER 7, 2022
There is not yet an FDA-approved treatment available for monkeypox, but existing antiviral agents have been found to be effective in vitro and in animal studies.
Pharmaceutical Technology
OCTOBER 7, 2022
Provention Bio and Sanofi US have signed a co-promotion agreement to launch the former’s lead investigational drug candidate, teplizumab for the delay in the onset of clinical type 1 diabetes (T1D). The agreement aids Provention in leveraging the capabilities and commercial resources of Sanofi to back teplizumab’s launch. The US Food and Drug Administration (FDA) is presently reviewing teplizumab for the delay of clinical T1D in people who are at risk.
Pharmacy Times
OCTOBER 7, 2022
The vaccine prevents whooping cough in infants younger than 2 months. It can be safely administered to mothers who are in their third trimester.
Pharmaceutical Technology
OCTOBER 7, 2022
The US Food and Drug Administration (FDA) has granted Fast Track designation for Eli Lilly and Company ’s tirzepatide to treat adults with obesity or overweight with weight-associated comorbidities. . On holding talks with the regulatory agency, the company intends to commence a rolling submission of a new drug application (NDA) for tirzepatide in adults for this indication this year.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
OCTOBER 7, 2022
For patients facing end-of-life care, psychedelic medicines may offer a chance to feel connected with themselves and others during such a difficult time.
pharmaphorum
OCTOBER 7, 2022
Two additional novel AI-generated targets for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) have been discovered using the Benevolent Platform and selected for AstraZeneca’s (AZ) drug discovery portfolio. These latest discoveries bring the total number of targets selected to date for AZ’s portfolio-entry under the collaboration up to five, with potential for future development milestones and sales-based royalty revenues for London-based BenevolentAI, also.
Pharmacy Times
OCTOBER 7, 2022
Michael Barr, MD, MBA, MACP, FRCP, discusses the importance of physicians and pharmacists sharing skills to increase positive patient outcomes.
STAT
OCTOBER 7, 2022
A Merck pill used to combat Covid-19 failed to demonstrate it can lower the risk of hospitalization compared with a placebo among adults at a higher risk from the disease, according to the results of a large study conducted in the U.K. The preliminary results of the randomized trial, which involved more than 25,000 participants, showed that taking molnupiravir did speed time to recovery by about six days, which means that patients did get some relief.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
OCTOBER 7, 2022
QR codes are currently used in various health care settings, such as in hospitals for patient verification, but more recently for health care-related education.
The Thyroid Pharmacist
OCTOBER 7, 2022
When I began my health journey with nutrition, I was skeptical. Could giving up gluten, dairy, and sugar really make a difference? If these foods were that problematic, I would have certainly learned about them in pharmacy school, right? Well, much to my surprise, within three days of giving up these three foods, my bloating, acid reflux, and irritable bowel syndrome vanished!
Pharmacy Times
OCTOBER 7, 2022
Rucaparib is the only PARP inhibitor demonstrated to have better outcomes than a docetaxel-containing control arm, according to researchers.
STAT
OCTOBER 7, 2022
In mid-April 2020, as Covid-19 shutdowns and lockdowns were being put in place across the U.S., my grandmother’s health started to decline. With so many unknowns , the assisted living facility where she lived, like most others, had a strict no-visitors policy. When it became clear that my grandmother was in her last hours of life, the facility figured out how to safely allow my aunt into the building for my grandmother’s last breaths.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
OCTOBER 7, 2022
Farah Towfic, PharmD, MBA, RPh, director, CEO Operations, US Pharmacopeia, details some of the moments that led her to the pharmacy field and the important role that mentorship played in that process.
pharmaphorum
OCTOBER 7, 2022
As we enter October and the Frontiers Health 2022 conference in Milan, we’re shining a spotlight on some of the Steering Committee members who have helped make the event what it is. Here we talk to Fredrik Debong, who cofounded MySugr in 2012 and sold it to Roche Diabetes Care five years later in an eight- to nine-figure deal. A cooling off in digital health investment.
European Pharmaceutical Review
OCTOBER 7, 2022
The National Institute of Health and Care Excellence (NICE) has recommended Bristol Myers Squibb’s Zeposia ® (ozanimod) for use in England and Wales to treat moderate to severe ulcerative colitis (UC) cases in adults who are intolerant of, or unresponsive to biologics or conventional therapies. UC is an Inflammatory Bowel Disease (IBD) that makes immune system attack the gastrointestinal (GI) tract.
STAT
OCTOBER 7, 2022
WASHINGTON — The federal government, which has long struggled to increase Covid-19 vaccinations in rural areas, is starting to take its shots to where the people are: NASCAR races. A vaccination tent at the NASCAR Cup Series in Arizona next month — attended by roughly 100,000 people — is the latest effort devised by Health and Human Services officials and advisers keen to reinvigorate booster rates that have stalled amid public fatigue and skepticism.
European Pharmaceutical Review
OCTOBER 7, 2022
A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 percent. Data showed that worldwide, oral solids are the most popular mode of drug delivery due to being highly cost-effective and offering simple manufacturing processes.
STAT
OCTOBER 7, 2022
Federal officials significantly reduced the quality scores of next year’s Medicare Advantage plans, a move that was widely expected but will still affect millions of older adults and people with disabilities who have migrated to the growing program. The lower scores also will drain billions of dollars in bonuses that flow to health insurers that get high marks.
Pharmaceutical Commerce
OCTOBER 7, 2022
While all drug development efforts are fraught with peril, a growing number of biopharma companies—large and small—are staking a claim in the rare disease treatment space, chasing odds that could yield clinical and financial rewards.
STAT
OCTOBER 7, 2022
The FDA has announced the set of rules it proposes to enforce for manufacturers to claim that a food product is “healthy.” The proposed rules are a lot better than the labeling anarchy that currently exists. But here’s my bottom line: health claims are not about health. They are about selling food products. The FDA says that a “healthy” product must meet two requirements: It must contain a meaningful amount of food, and it must not contain more than certain upp
pharmaphorum
OCTOBER 7, 2022
It’s often stated – mostly without reference to data – that the environment for innovative launches is more competitive now than it ever has been. Is this true? IQVIA has the long term market data, from World Reviews back to 1978, to investigate, and analysed nearly 30 years of launches into leading therapy classes, from multiple eras in the development of the pharmaceutical industry.
STAT
OCTOBER 7, 2022
A senior researcher who was most recently at Johnson & Johnson has emerged as a top candidate to be Biogen’s CEO, according to people familiar with the discussions. The selection of the researcher, Mathai Mammen, until recently the head of R&D at pharmaceutical giant Johnson & Johnson, would be a major departure for Biogen, which has tended to hire corporate operators rather than credentialed scientists to serve as CEO.
Pharma Times
OCTOBER 7, 2022
The companies will aim to improve treatment for patients with prostate, breast and lung cancer
STAT
OCTOBER 7, 2022
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
Pharma Times
OCTOBER 7, 2022
First EU public-private collaboration for production of saRNA-based vaccines
STAT
OCTOBER 7, 2022
Health plans trying to reach low-income and underserved customers say they’re being stymied by a decades-old federal rule limiting texting — and they’re framing it as a health equity issue in their bid to change it. Low-income and underserved patients, they say, are more likely to see and respond to texts about their health than they are to answer calls from unknown numbers or to receive mailed notices, especially if they’re at work or move frequently.
Pharmacy Times
OCTOBER 7, 2022
New research suggests that acetazolamide and standard loop-diuretic therapy may decrease congestion and prevent future hospitalizations in patients with acute decompensated heart failure.
Let's personalize your content